ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1668

Selective Inhibition of Tumor Necrosis Factor-α Receptor 2 (TNFR2) Activity Alleviates Psoriasiform Inflammation in Mouse Models

Unnikrishnan Chandrasekharan1, Chad Braley2, Jennifer Harvey3, Zeneng Wang1, Paul DiCorleto4 and M. Elaine Husni5, 1Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH, 2Department of Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, 3Department of Cellular and Molecular, Cleveland Clinic, Cleveland, OH, 4Division of Research and Sponsored Programs, Kent State, kent, OH, 5Rheumatology, Cleveland Clinic Foundation, Cleveland, OH

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Mouse model, psoriasis, psoriatic arthritis and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Tumor necrosis factor-α (TNF) activates two receptors globally, TNFR1 and TNFR2. Neutralizing antibodies or soluble TNF receptors can inactivate TNF, blocking activity of both receptors, and have been successful in treating psoriasis (PsO) and psoriatic arthritis (PsA). However, continued use of anti-TNF therapy has been associated with an increase in serious infections, such as reactivation of tuberculosis and malignancies. These side effects are related to TNFR1 blockade. Using mouse models, we showed that activity of both TNFR1 and TNFR2 is critical for TNF-mediated inflammatory responses.1 Recently, we identified that activation of PRMT5 (protein arginine methyltransferase 5), an enzyme critical for TNF-mediated inflammatory responses, is downstream of TNFR2 but not TNFR1 signaling. This makes PRMT5 a target for treating TNF-dependent inflammatory diseases. Our goal is to demonstrate that selective inactivation of TNFR2 via PRMT5 is effective in treating psoriatic diseases. Our objective is to determine the relative contributions of TNFR1 and TNFR2 to the development of PsO, and to test whether inhibition of PRMT5 activity will alleviate PsO and PsA in animal models.

Methods: To identify the role of TNF receptors in psoriasis we used the imiquimod (IMQ) mouse model. We applied IMQ (4 mg/day/mouse for 4 days) to 10-12 week old wild type (WT), TNFR1-null, TNFR2-null and TNFR1 & 2 double-null mice. To determine the role of PRMT5, we treated a specific PRMT5 small molecule inhibitor EPZ015666 topically 4 hours prior to IMQ application once a day for 4 days. Erythema, scaling and thickness of the IMQ or vehicle treated area was assessed by PASI (Psoriasis Area and Severity Index). Epidermal thickness was measured using ImagePro software on H&E stained skin sections. Immunohistochemistry was used to determine PRMT5 expression. Protein-incorporated SDMA (Symmetrical Dimethyl Arginine), which is the catalytic product of PRMT5 and works as a functional representation of PRMT5 activity, was measured in psoriatic skin using mass spectrometry. Further, we are currently testing whether EPZ015666 can inhibit PsA-like joint disease using a TNF overexpressing mouse strain (ihTNFtg mice2).

Results:  In WT mice, erythema, scaling, and thickness peaked at day 8 (PASI ~ 8.0). TNFR2-null or double-null mice skin inflammation was undetectable. TNFR1-null mice showed a PASI score of 1 – 2.5. H&E revealed significant keratinocyte hyperplasia and leukocyte infiltration in WT treated with IMQ, which were inhibited in TNFR2-null, TNFR1-null or double-null mice. Further, IMQ-treated mouse skin showed elevated PRMT5 expression. There was a ~ 2-fold increase of SDMA in mouse psoriatic skin compared to the adjacent normal skin. Importantly, topical application of PRMT5 inhibitor, EPZ015666, diminished the IMQ-induced PsO pathogenesis in WT mice (~ 75%).

Conclusion:  IMQ-induced psoriasis is critically dependent on TNFR2. An increase in the abundance of PRMT5 was also found in mouse psoriatic skin and the specific PRMT5 inhibitor that can block TNFR2 ameliorates psoriasis in mice.

References

1 Chandrasekharan, U. et al. Blood 109, p1944, 2007

2 Retser, E. et al. Arthr & rheum 65, p2300, 2013


Disclosure: U. Chandrasekharan, None; C. Braley, None; J. Harvey, None; Z. Wang, None; P. DiCorleto, None; M. E. Husni, Lilly, Novartis, Abbvie, Celgene, Bristol Myers Squibb, Amgen, Janssen, & UCB pharma, 5.

To cite this abstract in AMA style:

Chandrasekharan U, Braley C, Harvey J, Wang Z, DiCorleto P, Husni ME. Selective Inhibition of Tumor Necrosis Factor-α Receptor 2 (TNFR2) Activity Alleviates Psoriasiform Inflammation in Mouse Models [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/selective-inhibition-of-tumor-necrosis-factor-%ce%b1-receptor-2-tnfr2-activity-alleviates-psoriasiform-inflammation-in-mouse-models/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/selective-inhibition-of-tumor-necrosis-factor-%ce%b1-receptor-2-tnfr2-activity-alleviates-psoriasiform-inflammation-in-mouse-models/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology